Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Building a Follow-On Business: $3 Billion Reasons to Love Biosimilars

This article was originally published in RPM Report

Executive Summary

One Wall Street analyst thinks biosimilars could represent a $3 billion dollar business line for Amgen in less than a decade. Is that attractive enough to pursue a follow-on strategy for innovator companies? The answer is an unqualified yes.


Related Content

Biosimilars Naming Conventions On FTC Agenda – In More Ways Than One
Words Of Wisdom For Biosimilar Developers
BIO Responds On Naming
The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?
Where Are The Biosimilars?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts